PURPOSE: Deregulation of the cell cycle is one of the important prerequisites for cancer development. p21 and p27 are both universal inhibitors of cyclin-dependent kinases and can therefore influence cell cycle or tumor progression. The aim of this study was to determine the influence of p21 and p27 expression on survival and chemotherapy response. METHODS: 165 patients with ovarian cancer have been examined for p21 and p27 expression by immunohistochemistry on formalin-fixed, paraffin-embedded tissue using the monoclonal primary antibody WAF1 (Oncogene Science) and KIP1 (Transduction Laboratories). RESULTS: High p21 expression (>50%) correlates only with early tumor stage (P=0.04). There was no correlation found between p21 and p27 expression. Patients with high p27 expression (>25%) had a longer DFS (disease free survival) in both univariate and multivariate analysis (P=0.05 and P=0.043) than patients with low p27 expression. A longer overall survival (OS) could only be proven for the group of high p27 expression in univariate analysis (P=0.03). CONCLUSION: p27 is an independent prognostic factor for ovarian cancer for DFS though this was not true for OS.
PURPOSE: Deregulation of the cell cycle is one of the important prerequisites for cancer development. p21 and p27 are both universal inhibitors of cyclin-dependent kinases and can therefore influence cell cycle or tumor progression. The aim of this study was to determine the influence of p21 and p27 expression on survival and chemotherapy response. METHODS: 165 patients with ovarian cancer have been examined for p21 and p27 expression by immunohistochemistry on formalin-fixed, paraffin-embedded tissue using the monoclonal primary antibody WAF1 (Oncogene Science) and KIP1 (Transduction Laboratories). RESULTS: High p21 expression (>50%) correlates only with early tumor stage (P=0.04). There was no correlation found between p21 and p27 expression. Patients with high p27 expression (>25%) had a longer DFS (disease free survival) in both univariate and multivariate analysis (P=0.05 and P=0.043) than patients with low p27 expression. A longer overall survival (OS) could only be proven for the group of high p27 expression in univariate analysis (P=0.03). CONCLUSION:p27 is an independent prognostic factor for ovarian cancer for DFS though this was not true for OS.
Authors: V Masciullo; G Ferrandina; B Pucci; F Fanfani; S Lovergine; J Palazzo; G Zannoni; S Mancuso; G Scambia; A Giordano Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: B St Croix; V A Flørenes; J W Rak; M Flanagan; N Bhattacharya; J M Slingerland; R S Kerbel Journal: Nat Med Date: 1996-11 Impact factor: 53.440
Authors: V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano Journal: Cancer Res Date: 1997-08-15 Impact factor: 12.701
Authors: M Schuyer; M E van der Burg; S C Henzen-Logmans; J H Fieret; J G Klijn; M P Look; J A Foekens; G Stoter; E M Berns Journal: Br J Cancer Date: 2001-11-02 Impact factor: 7.640
Authors: Ashley S Felix; Mark E Sherman; Stephen M Hewitt; Munira Z Gunja; Hannah P Yang; Renata L Cora; Vicky Boudreau; Kris Ylaya; Jolanta Lissowska; Louise A Brinton; Nicolas Wentzensen Journal: Front Oncol Date: 2015-02-09 Impact factor: 6.244
Authors: Angela Casado-Adam; Lidia Rodriguez-Ortiz; Sebastian Rufian-Peña; Cristobal Muñoz-Casares; Teresa Caro-Cuenca; Rosa Ortega-Salas; Maria Auxiliadora Fernandez-Peralbo; Maria Dolores Luque-de-Castro; Juan M Sanchez-Hidalgo; Cesar Hervas-Martinez; Antonio Romero-Ruiz; Javier Briceño; Álvaro Arjona-Sánchez Journal: J Clin Med Date: 2022-09-29 Impact factor: 4.964
Authors: H Gakiopoulou; P Korkolopoulou; G Levidou; I Thymara; A Saetta; C Piperi; N Givalos; I Vassilopoulos; K Ventouri; A Tsenga; A Bamias; M-A Dimopoulos; E Agapitos; E Patsouris Journal: Br J Cancer Date: 2007-10-16 Impact factor: 7.640